Here, we designed and optimized a CAR-T-cell targeting the type II transmembrane glycoprotein, CLL1, a target recently used for cancer immunotherapies [11,12] that is expressed in 92% of AML patients [13]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.